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Objectives: Appropriate use of and access to antimicrobials are key priorities of global strategies to combat anti-
microbial resistance (AMR). The WHO recently classified key antibiotics into three categories (AWaRe) to improve
access (Access), monitor important antibiotics (Watch) and preserve effectiveness of ‘last resort’ antibiotics
(Reserve). This classification was assessed for antibiotic stewardship and quality improvement in English
hospitals.
Methods: Using an expert elicitation exercise, antibiotics used in England but not included in the WHO AWaRe
index were added to an appropriate category following a workshop consensus exercise with national experts.
The methodology was tested using national antibiotic prescribing data and presented by primary and secondary
care.
Results: In 2016, 46/108 antibiotics included within the WHO AWaRe index were routinely used in England and
an additional 25 antibiotics also commonly used in England were not included in the WHO AWaRe index. WHO
AWaRe-excluded and -included antibiotics were reviewed and reclassified according to the England-adapted
AWaRE index with the justification by experts for each addition or alteration. Applying the England-adapted
AWaRe index, Access antibiotics accounted for the majority (60.9%) of prescribing, followed by Watch (37.9%)
and Reserve (0.8%); 0.4% of antibiotics remained unclassified. There was unexplained 2-fold variation in
prescribing between hospitals within each AWaRe category, highlighting the potential for quality improvement.
Conclusions: We have adapted the WHO AWaRe index to create a specific index for England. The AWaRe index
provides high-level understanding of antibiotic prescribing. Subsequent to this process the England AWaRe index
is now embedded into national antibiotic stewardship policy and incentivized quality improvement schemes.
Introduction
Appropriate use of and access to antimicrobials is a key priority of
global strategies to combat antimicrobial resistance (AMR). The
WHO recently updated the Essential Medicines List (EML) and pro-
posed a novel metric for antimicrobial use: the AWaRe index.1 This
index classified key antibiotics into three categories: to improve
access (Access); to monitor important antibiotics (Watch); and to
preserve effectiveness of ‘last resort’ antibiotics (Reserve).2
The Access group consists of first and second choices for the
empirical treatment of the most common infection syndromes
and antibiotics that should consistently be widely available global-
ly. The Watch group are antibiotic classes considered to have
higher toxicity concerns and/or resistance potential. The Reserve
group includes new antibiotics and treatment options reserved for
complex infections or MDR.
The WHO recently demonstrated the use of the AWaRe index in
the analysis and interpretation of global antibiotic consumption
data.3 The AWaRe index was intended for use by WHO member
states to estimate the relative use of narrow-spectrum and broad-
spectrum antibiotics, to aid evaluation of progress in optimizing
antibiotic use and to help in defining goals for future quality
VC Crown copyright 2019.
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improvement.4,5 However, country-specific variation in AMR,
antibiotic use and treatment guidelines require each country to
review this index to ensure it is relevant and optimized for country-
specific use.
Antimicrobial prescribing quality measures in England are current-
ly enacted through national incentivized quality improvement goals.
A national Quality Premium, an incentivized quality improvement
programme for primary care in England, has been in place since the
financial year 2015–16, focusing on reducing total and broad-
spectrum (cephalosporins, quinolones and amoxicillin/clavulanate)
use. There has also been an Antimicrobial Commissioning for Quality
and Innovation (CQUIN) scheme in place since 2016/17; these
CQUINs have been focused on reducing total, piperacillin/tazobac-
tam and carbapenem consumption in secondary care.6,7
Recent antibiotic shortages, particularly of piperacillin/tazobac-
tam in 2017 in England, have not only highlighted the fragility of
antibiotic supply chains but also of prescribing quality measures
focused on single antibiotics.8 In this study we assessed the WHO
AWaRe index for use as an antimicrobial stewardship quality im-
provement indicator in England.
Methods
The NHS Business Services Authority and IQVIA provided national-level
antibiotic prescribing data for primary and secondary care in England
(2011–16). Prescribing data for clinical antibiotics only were included in this
study; no topical, anti-parasitic or anti-TB formulations were included.
Prescribing data were translated into DDDs using the WHO ATC/DDD index.
These data contain all dispensed antibiotic data from public (NHS) patients
within primary care (estimated at 95% of total antibiotic prescribing in the
community with no data included on private patients, based on compari-
sons with wholesale data) and public and private patients that are cared for
in NHS hospitals (estimated at 95% of hospital prescribing, based on similar
prescribing in inpatients and outpatients in the private sector for bed base
and patients reviewed). Almost 15 000 general practices or primary
care sites and 154 acute hospital trusts (management organizations for
secondary care), representing more than 370 clinical hospitals or hospital
outpatient locations, were included in the dataset with some variation over
time as primary care practices and hospital sites opened and closed.
The full list of antibiotics used is available in Table S1 (available as
Supplementary data at JAC Online). Mid-year population estimates were
provided by the Office for National Statistics (ONS). Hospital admission epi-
sodes were determined from monthly submissions from NHS hospitals to
NHS Digital. Data were analysed using Microsoft Excel and Stata V15.
The AWaRe index was adapted for national use in England by expert
elicitation with members of the Department of Health and Social Care
(DHSC) Advisory Committee on Antibiotic Prescribing, Resistance and
Healthcare-Associated Infection (APRHAI) and oversight group for the
English Surveillance Programme for Antimicrobial Use and Resistance
(ESPAUR). All antibiotics in current guidelines or which comprised greater
than 0.2% of total DDD consumption in England were reviewed and
assessed against the framework for decision-making provided in the
WHO Report on Surveillance of Antibiotic Consumption.3 Once reviewed,
PHE analysed the data and presented results to the expert group for further
discussion using two key metrics: DDDs per 1000 inhabitants per day for
comparing antibiotic use in primary and secondary care and DDDs per 1000
admissions for comparisons between hospital organizations. DDDs per
1000 admissions were log-transformed in order to normalize the values
and develop funnel plots to determine variation and outliers in hospital
prescribing across the England AWaRe index categories. Finally, national
quality improvement ambitions for prescribing of antibiotics from each of
the three AWaRe groups were developed based on the adapted England
AWaRe index and were proposed to the UK government for implementa-
tion within the NHS in England.
Results
In 2016, the total antibiotic consumption in England was 21.5
DDDs per 1000 inhabitants per day with 91% of prescribing
occurring in primary care. Forty-six antibiotics included within
the WHO AWaRe index were routinely used in England. However,
a further 25 antibiotics also commonly used in England were
not included in the AWaRe index, accounting for 12.4% of total
prescribing volume (Figure 1).
Adaptation of the AWaRe list for the UK was achieved using an
expert elicitation process for antibiotics that were not in the
WHO AWaRe categories. In total the status of 37 antibiotics was
determined or changed; the rationale for each of these changes is
outlined in Table 1. Changes were made predominantly in relation
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Figure 1. (a) Antibiotic consumption in England (primary and secondary care) as DDDs per 1000 population per day by WHO AWaRe category.
(b) Proportion of antibiotic DDDs per 1000 population per day in England (primary and secondary care) by WHO AWaRe category. Other, antibiotics
not included in the WHO AWaRe index. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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to: (i) antibiotics recommended in national guidance; (ii) policies
to reduce the risk of Clostridioides (Clostridium) difficile infec-
tion; (iii) the presence of emerging or established AMR; or
(iv) preserving the use of certain antibiotics for MDR infections.
In addition, given a national antibiotic stewardship policy
priority to reduce use of piperacillin/tazobactam and carbape-
nems, these were moved from Access to Watch and Reserve
categories, respectively.
Using the modified England AWaRe index, Access antibiotics
accounted for the majority (60.9%) of prescribing across all English
healthcare sectors in 2016, compared with 68.7% using the WHO
AWaRe index, followed by Watch (37.9% versus 18.4%), Reserve
(0.8% versus 0.4%) and Other (0.4% versus 12.4%) (Table 2 and
Figure 1b). However, these results primarily reflect antibiotics dis-
pensed in community or primary healthcare settings, where more
than 80% of prescribing occurs. Furthermore, the proportion of
antibiotics within the Access category increased year on year from
2011 to 2016 from 60.2% to 63.3% of total prescribing (5% in-
crease). Conversely, antibiotics prescribed from the Watch and
Reserve categories declined by 8% (from 39.2% to 36.0% of total
Table 1. Recategorization of antibiotics within the AWaRe index for use in English national stewardship policy
ATC name ATC code
AWaRe
WHO
AWaRe
England Rationale for movement
Amikacin J01GB06 Access Watch antibiotic used for resistant Gram-negative infections
Amoxicillin and
enzyme inhibitor
J01CR02 Access Watch to avoid overuse as resistance increasing and associated with
increased risk of C. difficile infections
Ampicillin combinations J01CA51 Other Access similar category as amoxicillin; rare use
Cefaclor J01DC04 Other Watch associated with increased risk of C. difficile infections
Cefadroxil J01DB05 Other Watch associated with increased risk of C. difficile infections
Cefalexin J01DB01 Access Watch associated with increased risk of C. difficile infections
Cefamandole J01DC03 Other Watch associated with increased risk of C. difficile infections
Cefazolin J01DB04 Access Watch associated with increased risk of C. difficile infections
Cefoxitin J01DC01 Other Watch associated with increased risk of C. difficile infections
Cefprozil J01DC10 Other Watch associated with increased risk of C. difficile infections
Cefradine J01DB09 Other Watch associated with increased risk of C. difficile infections
Cefuroxime J01DC02 Other Watch associated with increased risk of C. difficile infections
Ceftazidime and
enzyme inhibitor
J01DD52 Watch Reserve novel combination reserved for treatment failures
Chloramphenicol J01BA01 Access Watch second-line antibiotic, use in penicillin allergy
Clindamycin J01FF01 Access Watch associated with increased risk of C. difficile infections
Dalbavancin J01XA04 Watch Reserve novel antibiotic reserved for treatment failures and OPAT
Doripenem J01DH04 Watch Reserve reserved to conserve use for resistant Gram-negative infections
Ertapenem J01DH03 Watch Reserve reserved to conserve use for resistant Gram-negative infections
Fosfomycin (oral) J01XX01 Other Access narrow spectrum, recommended for uncomplicated UTI
Fusidic acid J01XC01 Other Access narrow spectrum
Imipenem J01DH51 Watch Reserve reserved to conserve use for resistant Gram-negative infections
Lymecycline J01AA04 Other Watch used for acne, alternative non-antimicrobial drugs available
Meropenem J01DH02 Watch Reserve reserved to conserve use for resistant Gram-negative infections
Minocycline J01AA08 Other Watch used for acne, alternative non-antimicrobial drugs available
Neomycin J01GB05 Other Access not routinely used in England, monitor carefully for change in use
Oxytetracycline J01AA06 Other Watch used for acne, alternative non-antimicrobial drugs available
Piperacillin J01CA12 Other Watch avoid overuse as resistance increasing
Pivmecillinam J01CA08 Other Access narrow spectrum, recommended for uncomplicated UTI
Pristinamycin J01FG01 Other Watch not routinely used in England, monitor carefully for change in use
Quinupristin J01FG02 Other Watch not routinely used in England, monitor carefully for change in use
Telavancin J01XA03 Watch Reserve not routinely used in England, monitor carefully for change in use
Temocillin J01CA17 Other Watch antibiotic used for resistant Gram-negative infections
Tetracycline J01AA07 Other Access narrow spectrum, recommended in treatment guidelines
Ticarcillin J01CA13 Other Watch not routinely used in England, monitor carefully for change in use
Tobramycin J01GB01 Other Watch antibiotic used for resistant Gram-negative infections
Tetracycline combinations J01AA20 Other Watch used for acne, alternative non-antimicrobial drugs available
Any antibiotics categorized as both Access and Watch within the WHO AWaRe index were automatically classified as Watch antibiotics for UK stew-
ardship purposes. The rationale for all other reclassifications is presented in this table. OPAT, outpatient parenteral antimicrobial therapy.
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prescribing) and 13% (from 0.33% to 0.28% of total prescribing),
respectively. This coincided with a policy focus and corresponding
response in the primary and community healthcare sector on
reducing broad-spectrum antibiotics.
In the acute hospital sector, unsurprisingly, more Watch and
Reserve antibiotics were used; in 2016, Access antibiotics
accounted for the majority (49.7%), followed by Watch (46.9%),
Reserve (3.3%) and Other (0.1%) (Table 2). In addition, between
2011 and 2016 hospital prescribing within the Access category
decreased by 4%, the Watch category increased by 3% and the
Reserve category increased by 28% though still remained ,3% of
total prescribing.
There was a high degree of variation in prescribing between
hospitals within each AWaRe category. In particular, specialist hos-
pitals, predominantly cardiothoracic, haematology/oncology and
paediatric monospecialities, were high outliers in the use of
Reserve antibiotics and tended to use fewer Access antibiotics. In
addition, there remains variation in total prescribing per 1000
admissions across the country, highlighting potential for quality
improvement nationally (Figure 2); these funnel plots demonstrate
the large variation in antibiotic use across hospital organizations,
by England AWaRe category and hospital organization type. These
data suggested that there was an opportunity to reduce unwar-
ranted variation in antimicrobial prescribing in secondary care;
monitoring of the proportion of antibiotic use in each AWaRe cat-
egory was therefore recommended to form part of future quality
improvement incentive schemes.
Discussion
The AWaRe index supports high-level understanding of antibiotic
prescribing, essentially providing a summary of broad- and
narrow-spectrum prescribing as a proxy measure for antibiotic pre-
scribing quality. The WHO has acknowledged that the EML AWaRe
index will require local adaptation and further revision over time.2
The WHO published their first global assessment of antimicrobial
use in 2018, recognizing the limitations in the data that were avail-
able.3 However, within this publication, the antibiotics that were
not included in the original index varied in consumption across
countries from 1% to 40%, limiting direct comparisons of results.
We have adapted the AWaRe index for antibiotic stewardship
purposes in England using national- and hospital-level data to in-
clude antibiotics pertinent to use in English healthcare settings.
Although the greatest volume of antibiotics is prescribed in com-
munity healthcare settings in England,8 this sector prescribed a
higher proportion of Access antibiotics and a lower proportion of
Watch and Reserve antibiotics than the acute secondary care set-
ting. The national Quality Premium for primary care has focused
on a reduction in total prescribing and also prescribing of cephalo-
sporins, quinolones and amoxicillin/clavulanate, all of which are in
the Watch England AWaRe category. National prescribing data
suggest that a relatively high and increasing proportion of narrow-
spectrum antibiotics are prescribed in primary care. The variation
in the use of Access antibiotics between primary and secondary
care most likely relates to different patient acuity, complexity and
the prevalence of MDR bacteria in these care settings.
NHS acute hospitals prescribed a lower proportion of Access
antibiotics and higher proportions of Watch and Reserve antibiotics
than the primary care setting. In addition, a recent study has
shown an association between NHS acute hospitals with stronger
‘process’ elements within their antimicrobial stewardship pro-
grammes and a lower proportion of antibiotic prescribing from
within the Reserve category.9 Therefore, application of the AWaRe
index in national stewardship initiatives has been focused on the
acute secondary care setting.
In April 2018, NHS England introduced a new quality improve-
ment indicator for NHS acute hospitals to achieve in 2018–19.
These organizations have been asked to increase the proportion of
antibiotic usage within the Access group of the AWaRe (England)
index such that the Access group comprises 55% of total anti-
biotic consumption (expressed as DDDs per 1000 admissions) or
an absolute increase of three percentage points from 2016 base-
line levels.7 This variation in targets related to their baseline allows
them to deliver a quality improvement based on their own baseline
rather than comparing them with their peers, as patient-level anti-
biotic consumption and thus appropriate adjustment is not yet
available for national monitoring. Furthermore, in January 2019
the UK government announced a new 5 year national action plan
for AMR (2019–24), which included a target for a 10% reduction in
the use of Reserve and Watch antibiotics in hospitals from a 2017
baseline.10
A disadvantage of any such measure is that they do not take
into consideration the age and sex mix of populations of patients
served by hospitals, and other factors such as deprivation and
complexity of care, that can drive hospital antibiotic prescribing.
Nonetheless as each hospital is required to improve from its
own baseline levels this is consistent with improving the quality
Table 2. Proportion of DDDs per 1000 population prescribed within
AWaRe England categories across healthcare sectors over time
Year All England (%) Primary care (%) Secondary care (%)
Access 2011 58.77 60.17 51.63
2012 59.24 60.82 50.80
2013 59.05 60.76 50.38
2014 59.39 61.17 50.46
2015 59.81 61.90 49.72
2016 60.88 63.29 49.72
Watch 2011 40.24 39.18 45.65
2012 39.82 38.58 46.39
2013 39.95 38.65 46.56
2014 39.58 38.25 46.26
2015 39.05 37.45 46.79
2016 37.94 36.01 46.86
Reserve 2011 0.70 0.33 2.61
2012 0.70 0.32 2.73
2013 0.76 0.32 2.97
2014 0.78 0.30 3.21
2015 0.83 0.29 3.43
2016 0.83 0.28 3.33
Other 2011 0.29 0.33 0.12
2012 0.25 0.28 0.09
2013 0.24 0.27 0.09
2014 0.25 0.29 0.07
2015 0.31 0.36 0.06
2016 0.36 0.42 0.08
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of antibiotic prescribing in each hospital. Further consideration
is required to adapt the AWaRe index for use in specialist
healthcare settings, including an improved understanding of
case-mix. However, until routine electronic prescribing of antibi-
otics is available nationally, there is limited work that can be
performed in this area.
The proportion of total antibiotic prescribing from the Access
category of the AWaRe index (as modified for England) is published
as an indicator for each hospital on the PHE open access data por-
tal Fingertips;11 thereby allowing NHS hospitals to track progress
towards their CQUIN quality improvement goals and enabling
comparisons and shared learning with their selected peers
(http://fingertips.phe.org.uk/profile/amr-local-indicators). In England,
multimodal activities are recommended to improve antimicrobial
stewardship activities including development of national and
local guidelines, antimicrobial restriction, selective reporting of
antimicrobial susceptibility results, prescriber education, audit
and feedback.12
We recommend that countries should review the AWaRe cate-
gorizations in their country, potentially using similar methodology,
and consider which antibiotics from each category should be
moved into the relevant category based on resistance profiles and
antibiotic use. Quality improvement methodology can then be
applied to organizations to improve antimicrobial stewardship
and, in particular, preserve antibiotics in the Watch and Reserve
categories.
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